The Janus kinase 2 (JAK2) pseudokinase domain (JH2) is an ATP-binding domain that regulates the activity of the catalytic tyrosine kinase domain (JH1). Dysregulation of JAK2 JH1 signaling caused by the V617F mutation in JH2 is implicated in various myeloproliferative neoplasms. To explore if JAK2 activity can be modulated by a small molecule binding to the ATP site in JH2, we have developed several ligand series aimed at selectively targeting the JAK2 JH2 domain. We report here the evolution of a false virtual screen hit into a new JAK2 JH2 series. Optimization guided by computational modeling has yielded analogues with nanomolar affinity for the JAK2 JH2 domain and >100-fold selectivity for the JH2 domain over the JH1 domain. A crystal structure for one of the potent compounds bound to JAK2 JH2 clarifies the origins of the strong binding and selectivity. The compounds expand the platform for seeking molecules to regulate JAK2 signaling, including V617F JAK2 hyperactivation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109162 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.2c00051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel germline JAK2 mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon.
Am J Hematol
July 2024
Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Article Synopsis
- - Polycythemia vera (PV) is caused by mutations in the JAK2 gene, often leading to elevated red blood cell counts; however, a 38-year-old woman presented with a novel mutation in the JAK2 pseudokinase domain instead of the common ones.
- - Genetic testing revealed this mutation was inherited, as her mother and son also displayed similar symptoms of erythrocytosis, and their blood showed abnormal growth patterns typical of PV.
- - Treatment with Ropeginterferon-alfa-2b (Ropeg-IFN-α) successfully induced remission and reduced JAK2 activity, highlighting a unique interaction between this therapy and JAK2 signaling that differs from typical treatments for PV.
A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Cell Commun Signal
October 2023
Department of Immunology and Inflammation, Shanghai Qilu Pharmaceutical R&D Center Limited, Shanghai, China.
Background: As a member of the Janus kinase (JAK) family, which includes JAK1, JAK2 and JAK3, tyrosine kinase 2 (TYK2) plays an important role in signal transduction and immune system regulation. Moreover, it is also involved in the development of many types of inflammatory and autoimmune diseases, such as psoriasis and systemic lupus erythematosus (SLE). TYK2 is an attractive therapeutic target, and selective inhibition of TYK2 over other JAK family members is critical for the development of TYK2 small molecule inhibitors.
View Article and Find Full Text PDFExploring conformation changes of Janus kinase 2 pseudokinase mediated by mutations through Gaussian accelerated molecular dynamics and principal component analysis.
J Biomol Struct Dyn
November 2024
School of Science, Shandong Jiaotong University, Jinan, China.
The pseudokinase domain (JH2) of the protein tyrosine kinase (Janus kinase 2, JAK2) regulates the activity of a tyrosine kinase domain (JH1) in JAK2, which is further affected by mutations in the JH2. In this work, Gaussian accelerated molecular dynamics (GaMD) simulations followed by construction of free energy landscapes (FELs) and principal component analysis (PCA) were performed to study effect of two mutations V617F and V617F/E596A on the conformations of the ATP-bound JH2. The dynamic analyses reveal that mutations affect the structural flexibility and correlated motions of the JH2, meanwhile also change the dynamics behavior of the P-loop and αC-helix of the JH2.
View Article and Find Full Text PDFAssociation between Polymorphism in the Janus Kinase 2 () Gene and Selected Performance Traits in Cattle and Sheep.
Animals (Basel)
July 2023
National Research Institute of Animal Production, Kraków, Experimental Department, Kołbacz, 1 Warcisława Street, 74-106 Stare Czarnowo, Poland.
The Janus Kinase 2 (JAK2) tyrosine kinase is an essential component of signal transduction of the class II cytokine receptors, including the growth hormone receptor. Therefore, it may play a crucial role in the signaling pathway of the somatotropic axis, which influences growth, development, and reproductive traits in ruminants. For this purpose, for three breeds of cattle (Hereford, Angus, and Limousin; a total of 781 individuals), two polymorphic sites located in exon 16 (rs210148032; p.
View Article and Find Full Text PDFSelectivity and Ranking of Tight-Binding JAK-STAT Inhibitors Using Markovian Milestoning with Voronoi Tessellations.
J Chem Inf Model
April 2023
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, United States.
Janus kinases (JAK), a group of proteins in the nonreceptor tyrosine kinase (NRTKs) family, play a crucial role in growth, survival, and angiogenesis. They are activated by cytokines through the Janus kinase-signal transducer and activator of a transcription (JAK-STAT) signaling pathway. JAK-STAT signaling pathways have significant roles in the regulation of cell division, apoptosis, and immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!